The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001257358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/09/2026
Date registered
Help: Date registered
15/10/2026
Date last updated
Help: Date last updated
15/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CBT-248 in Healthy Adult Participants
Scientific title
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CBT-248 in Healthy Adult Participants
Additional trial identifiers [1] 318465 0
CBT-248-HV-P1
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Chronic pancreatitis 343637 0
Condition category
Condition code
Oral and Gastrointestinal 339751 339751 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 339914 339914 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a single-site, randomised, double-blind, placebo-controlled, Phase 1 single ascending dose study to investigate the safety, tolerability, and pharmacokinetics of CBT-248 in healthy adult volunteers. CBT-248 is an oral vegetable (cellulose) capsule and will be administered as a single dose under fasted conditions.

A total of 24 healthy volunteers will be enrolled across three SAD cohorts included in this registration: Cohort A1, Cohort A2, and Cohort A4, with up to 8 participants per cohort. Within each cohort, participants will be randomised in a 6:2 ratio to receive CBT-248 or matching placebo.

The planned SAD dose levels included in this registration are 150 mg, 450 mg, and 2000 mg. The 1000 mg dose level will be evaluated separately in Cohort A3 as part of the food-effect component of the same protocol. Available safety, tolerability, and PK data from Cohort A3 Period 1 will contribute to dose-escalation review before proceeding to Cohort A4.

Each dose level will commence with 2 sentinel participants, with one participant randomised to CBT-248 and one participant randomised to placebo. Sentinel participants will be monitored in clinic for at least 24 hours after dosing, and the Principal Investigator will review available safety and tolerability data before dosing the remainder of the cohort.

Dose-escalation decisions will be made by the Safety Review Committee based on emerging safety, tolerability, laboratory, ECG, adverse event, and pharmacokinetic data. Dose levels may be adjusted based on review of emerging data.
Intervention code [1] 335394 0
Treatment: Drugs
Description of the comparator or control
The control treatment (placebo) will be a vegetable (cellulose) capsule that is visually identical to the study treatment, but it will not contain the active ingredient.


Participants in the SAD group will receive one dose of placebo on Day 1 of the study.
Control group
Placebo

Outcomes
Primary outcome [1] 346957 0
Measure the incidence, severity, and relationship of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs; including withdrawals due to AEs), measured as a composite outcome.
Timepoint [1] 346957 0
AEs will be monitored continuously from baseline (Day -1) to end-of-study (Day 7, one week after the dose of CBT-248).
Secondary outcome [1] 468347 0
Measure how the body interacts with CBT-248 as a single oral dose in healthy adult participants.
Timepoint [1] 468347 0
PK blood samples will be collected at the following time points: Day -6; Day -2 (Admission); 1 hour pre-dose on Day 1; 5, 15 and 30 minutes post-dose; 1, 1.5, 2, 4, 6, 8, 10, 16 and 24 hours post-dose; and Day 7 (follow-up).

Eligibility
Key inclusion criteria
* Adult males and females, 18 to 55 years of age (inclusive) at Screening.
* Body mass index (BMI) between 18.0 and 32.0 kg/m2 (inclusive) at Screening.
* Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant (CS) abnormalities after physical examination.
* Female volunteers must be of non-childbearing potential or be willing to avoid pregnancy by using adequate contraception.
* Male volunteers must agree not to donate sperm and to use adequate contraception with female partners.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
* Known hypersensitivity to the study drug or any of the study drug ingredients, or history of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer’s ability to participate in the study.

* Clinically significant infection and/or cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the participant’s risk if they were to participate in the study.

* History or current evidence of a clinically significant breast mass, unexplained nipple discharge, suspicious breast imaging, or other findings suggestive of clinically significant breast pathology that, in the opinion of the Investigator, could increase participant risk or interfere with study participation.

* Unable or unwilling to comply with the required soy-restricted dietary periods specified in the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All study participants who sign a participant informed consent form (PICF) will receive a unique sequential number (i.e., a screening number).

Participants who meet the study eligibility criteria will be assigned a randomisation number, which corresponds to a study treatment (CBT-248 or placebo) in accordance with the randomisation schedule. Randomisation will be performed prior to dosing on Day 1. Randomisation will be performed using a paper-based randomisation schedule provided to unblinded site staff.

The randomisation schedule will be prepared by unblinded statistician(s) and will be maintained under controlled access. Blinded study staff will not have access to the randomisation schedule until after database lock.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The allocation to CBT-248 or placebo will be performed using a block randomisation algorithm.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 323048 0
Commercial sector/Industry
Name [1] 323048 0
Cibus Therapeutics, Inc
Country [1] 323048 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Cibus Therapeutics, Inc.
Address
Country
United States of America
Secondary sponsor category [1] 325989 0
Commercial sector/Industry
Name [1] 325989 0
Avance Clinical Pty Ltd
Address [1] 325989 0
Country [1] 325989 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321450 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 321450 0
Ethics committee country [1] 321450 0
Australia
Date submitted for ethics approval [1] 321450 0
02/09/2026
Approval date [1] 321450 0
13/10/2026
Ethics approval number [1] 321450 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153762 0
Dr Aarthy Joseph
Address 153762 0
Nucleus Network St Kilda, Level 3, 549 St Kilda Road, Melbourne, Victoria, 3004
Country 153762 0
Australia
Phone 153762 0
+61 3 8593 9801
Fax 153762 0
Email 153762 0
Contact person for public queries
Name 153763 0
Dr Aarthy Joseph
Address 153763 0
Nucleus Network St Kilda, Level 3, 549 St Kilda Road, Melbourne, Victoria, 3004
Country 153763 0
Australia
Phone 153763 0
+61 3 8593 9801
Fax 153763 0
Email 153763 0
Contact person for scientific queries
Name 153764 0
Honit Piplani
Address 153764 0
Cibus Therapeutics, Inc., 3160 Porter Dr, Suite 140, Palo Alto, CA 94304, United States of America
Country 153764 0
United States of America
Phone 153764 0
+1 669 300 8336
Fax 153764 0
Email 153764 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.